Despite the name, there is no FDA-approved GLP-1 patch containing semiglutide, tirzepatide, or any other GLP-1 receptor agonist
Common side effects are primarily gastrointestinal: Nausea (most common, typically improves with titration) Diarrhea or constipation Abdominal discomfort Reduced appetite (intended therapeutic effect) Serious but rare adverse events include: Pancreatitis Gallbladder disease (especially during rapid weight loss) Boxed warning for thyroid C-cell tumors (observed in rodent studies, not confirmed in humans) From $299 Why These Compounds Do Not Interact Drug interactions occur through several mechanisms: receptor competition, enzyme competition, altered absorption, or pharmacodynamic overlap
To understand where these fit, it helps to look at what compounding pharmacies can legally do, what recent FDA shortage decisions changed, and how compounded products actually compare to brands
Liraglutide (Saxenda, Victoza) Liraglutide was one of the first GLP-1 receptor agonists widely used for weight management (Saxenda) and type 2 diabetes (Victoza)
These can be different for one person than another
